Background In recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), early identification of treatment response remains challenging because imaging may be delayed or confounded by treatment-related changes and atypical response patterns under immunotherapy. Serial circulating tumor DNA (ctDNA) analy...
Luca Leonardo Amodio, Lea Grossmann, Stefanie Gächter et al.· Frontiers in Oncology· 0 citations
In recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), early identification of treatment response remains challenging because imaging may be delayed or confounded by treatment-related changes and atypical response patterns under immunotherapy. Serial circulating tumor DNA (ctDNA) analysis may...
Luca Leonardo Amodio, Lea Grossmann, Stefanie Gächter et al.· Frontiers in Oncology· 0 citations
INTRODUCTION
The tumor suppressor TP53 is the most frequently mutated gene in human cancer, and drugs targeting specific mutant p53 proteins have been developed. Rezatapopt, which reactivates the Y220C p53 protein, was recently evaluated in the Phase I PYNNACLE trial in patients with solid tumors, with promising result...
M. Molina-Vila, Z. Tsourti, A. Stenzinger et al.· Journal of Thoracic Oncology· 0 citations
It is suggested that oncogene amplifications, rather than traditional genomic instability metrics, are associated with poor overall survival in MIBC, warranting validation in larger cohorts to assess their potential relevance as prognostic markers and therapeutic targets.
C. Poyet, A. S. Franzen, U. Bieri et al.· Journal of Cancer Research a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.